FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600140196> ?p ?o ?g. }

• W2600140196 endingPage "4628" @default.
• W2600140196 startingPage "4628" @default.
• W2600140196 abstract "Abstract Introduction Bortezomib (B) has been reported to be very effective in AL amyloidosis with overall response rates (ORR) varying between 50-80%. However, no prospective data have been published from multicenter studies on B treatment in de novo patients. Previously, we have demonstrated the positive long term effect of induction therapy followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT). We therefore investigated the efficacy and safety of B-Dexamethasone (BD) induction treatment followed by HDM + SCT to improve the complete response rate (CR) in de novo AL amyloidosis patients. This report is on the first 25 patients. Methods The HOVON 104 trial was performed in the Netherlands, Belgium and Germany from Jan 2012 to April 2016 and started with a randomized phase III design of BD versus dexamethasone (D) induction treatment followed by HDM + SCT. Due to slow accrual the D arm closed after including 7 patients. Patients with biopsy proven AL amyloidosis, aged between 18-70 years, with detectable M-protein and/or level of involved FLC > 50 mg/L, WHO performance status 0-2, NYHA stage 1-2 and ejection fraction > 45% were included. Major exclusion criteria were symptomatic orthostatic hypotension, NT proBNP level > 5000 pg/ml, Troponin T> 0.06 ug/l, Bilirubin > 2x ULN, eGFR < 30 ml/min, CTCAE grade peripheral sensory neuropathy > grade 2 or > grade 1 with pain. Inclusion and exclusion criteria were installed both at entry and before stem cell mobilization (SCM). B was given subcutaneously 1.3 mg/m2 twice a week for 2 weeks in a 21-day cycle, D 20 mg orally on each B and the following day. HDM dosage was 200 mg/m2. Hematological responses were defined according to consensus criteria with the addition of very good partial response (VGPR), defined as the difference between involved and uninvolved FLC (dFLC) < 40 mg/L. Cardiac, renal and liver response and progression criteria were defined according to consensus criteria with addition of NT proBNP. The primary endpoint was the proportion of patients with CR at 6 months after SCT. To demonstrate improvement from 30 to 50% with 80% power, 44 eligible patients were needed and 50 patients were registered. Results Median age was 60 years (range 26-70) and 68% were male. WHO performance status (PS) was 0-1 in 88% of patients and NYHA stage 1 in 52% and 2 in 44% of patients. Mayo cardiac risk score (2004) was I (28%), II (32%), III (36%). Organ involvement was 88% renal, 76% heart, 20% liver, 12% neurological, 4% gastrointestinal and 72% of patients had 2 or more organs involved. Bone marrow plasmacells were > 10% in 11 patients. Six of the 25 (24%) patients could not proceed to SCM. One patient due to low PS, one because of B related toxicity, two due to amyloidosis related complications and two patients died, both amyloidosis related. Of these 19 patients, 2 went subsequently off protocol because of ineligibility for HDM and one due to hematological progression. Sixteen out of 25 patients (64%) received HDM + SCT which was performed without any treatment related mortality (TRM). In total 29 SAEs were reported in 18 patients. The ORR after induction was 72% and ≥ VGPR in 56% of patients. The ORR in the 16 patients at 6 months after SCT was 75% and ≥ VGPR 63%. Median time to first response was 1 month. Intention to treat analysis demonstrated that the primary endpoint was met in 6 (24%) patients. Organ responses after induction were 9/22 renal and 3/19 heart, and at 6 months after SCT 9/14 renal and 5/13 heart. The first two BD cycles were given as planned in most patients, 80 and 70%, respectively, but doses were reduced and delayed thereafter for B in half of patients, mostly because of neurotoxicity. Mean cumulative dosage of B was 80% of planned. Also D was reduced in almost half of patients due to toxicity. The most common AEs during induction are shown in Table 1. Conclusions Analysis of 25 patients demonstrates that with BD treatment the dropout rate before HDM is 36% which is comparable to previous induction treatments. We therefore conclude that BD, given twice weekly, despite good efficacy, cannot prevent early amyloidosis related toxicity. The SCT procedure was without TRM. The hematological response rate is comparable to previously reported and renal response are 41% after BD and 64% at 6 months after SCT. Trial registration www.trialregister.nl ( NTR 3220), EudraCT 2010-021445-42 , supported by the Dutch Cancer Society (UU 2010-4884 ) and by an unrestricted grant from Janssen-Cilag Disclosures Minnema: Celgene: Consultancy; BMS: Consultancy; Amgen: Consultancy; Jansen Cilag: Consultancy. Hazenberg:GSK: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau. Hegenbart:Jansen Cilag: Honoraria, Other: financial support of conference participation. Ypma:Advisory Board Sanofi (Plerixafor): Membership on an entity's Board of Directors or advisory committees. Zweegman:Celgene: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Takeda: Honoraria, Research Funding. Broijl:Celgene: Honoraria; Jansen Cilag: Honoraria; Amgen: Honoraria. Sonneveld:Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria, Research Funding. Schoenland:Jansen: Honoraria, Other: financial support of conference participation, Research Funding; Prothena: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; GSK: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2600140196 created "2017-04-07" @default.
• W2600140196 creator A5002972322 @default.
• W2600140196 creator A5018467091 @default.
• W2600140196 creator A5022643534 @default.
• W2600140196 creator A5024780153 @default.
• W2600140196 creator A5032770450 @default.
• W2600140196 creator A5047666215 @default.
• W2600140196 creator A5049413660 @default.
• W2600140196 creator A5049740797 @default.
• W2600140196 creator A5066299287 @default.
• W2600140196 creator A5068940705 @default.
• W2600140196 creator A5077620734 @default.
• W2600140196 creator A5082157943 @default.
• W2600140196 creator A5083385949 @default.
• W2600140196 date "2016-12-02" @default.
• W2600140196 modified "2023-10-01" @default.
• W2600140196 title "HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis" @default.
• W2600140196 doi "https://doi.org/10.1182/blood.v128.22.4628.4628" @default.
• W2600140196 hasPublicationYear "2016" @default.
• W2600140196 type Work @default.
• W2600140196 sameAs 2600140196 @default.
• W2600140196 citedByCount "1" @default.
• W2600140196 countsByYear W26001401962017 @default.
• W2600140196 crossrefType "journal-article" @default.
• W2600140196 hasAuthorship W2600140196A5002972322 @default.
• W2600140196 hasAuthorship W2600140196A5018467091 @default.
• W2600140196 hasAuthorship W2600140196A5022643534 @default.
• W2600140196 hasAuthorship W2600140196A5024780153 @default.
• W2600140196 hasAuthorship W2600140196A5032770450 @default.
• W2600140196 hasAuthorship W2600140196A5047666215 @default.
• W2600140196 hasAuthorship W2600140196A5049413660 @default.
• W2600140196 hasAuthorship W2600140196A5049740797 @default.
• W2600140196 hasAuthorship W2600140196A5066299287 @default.
• W2600140196 hasAuthorship W2600140196A5068940705 @default.
• W2600140196 hasAuthorship W2600140196A5077620734 @default.
• W2600140196 hasAuthorship W2600140196A5082157943 @default.
• W2600140196 hasAuthorship W2600140196A5083385949 @default.
• W2600140196 hasConcept C126322002 @default.
• W2600140196 hasConcept C141071460 @default.
• W2600140196 hasConcept C159654299 @default.
• W2600140196 hasConcept C168563851 @default.
• W2600140196 hasConcept C203014093 @default.
• W2600140196 hasConcept C2775965419 @default.
• W2600140196 hasConcept C2776364478 @default.
• W2600140196 hasConcept C2777478702 @default.
• W2600140196 hasConcept C2779050716 @default.
• W2600140196 hasConcept C2779551797 @default.
• W2600140196 hasConcept C2780401358 @default.
• W2600140196 hasConcept C2911091166 @default.
• W2600140196 hasConcept C2992435398 @default.
• W2600140196 hasConcept C36394416 @default.
• W2600140196 hasConcept C71924100 @default.
• W2600140196 hasConcept C90924648 @default.
• W2600140196 hasConceptScore W2600140196C126322002 @default.
• W2600140196 hasConceptScore W2600140196C141071460 @default.
• W2600140196 hasConceptScore W2600140196C159654299 @default.
• W2600140196 hasConceptScore W2600140196C168563851 @default.
• W2600140196 hasConceptScore W2600140196C203014093 @default.
• W2600140196 hasConceptScore W2600140196C2775965419 @default.
• W2600140196 hasConceptScore W2600140196C2776364478 @default.
• W2600140196 hasConceptScore W2600140196C2777478702 @default.
• W2600140196 hasConceptScore W2600140196C2779050716 @default.
• W2600140196 hasConceptScore W2600140196C2779551797 @default.
• W2600140196 hasConceptScore W2600140196C2780401358 @default.
• W2600140196 hasConceptScore W2600140196C2911091166 @default.
• W2600140196 hasConceptScore W2600140196C2992435398 @default.
• W2600140196 hasConceptScore W2600140196C36394416 @default.
• W2600140196 hasConceptScore W2600140196C71924100 @default.
• W2600140196 hasConceptScore W2600140196C90924648 @default.
• W2600140196 hasIssue "22" @default.
• W2600140196 hasLocation W26001401961 @default.
• W2600140196 hasOpenAccess W2600140196 @default.
• W2600140196 hasPrimaryLocation W26001401961 @default.
• W2600140196 hasRelatedWork W149422118 @default.
• W2600140196 hasRelatedWork W2014454786 @default.
• W2600140196 hasRelatedWork W2032929770 @default.
• W2600140196 hasRelatedWork W2067463209 @default.
• W2600140196 hasRelatedWork W2071006295 @default.
• W2600140196 hasRelatedWork W2071434932 @default.
• W2600140196 hasRelatedWork W2160188479 @default.
• W2600140196 hasRelatedWork W2470933183 @default.
• W2600140196 hasRelatedWork W2981030380 @default.
• W2600140196 hasRelatedWork W2304017568 @default.
• W2600140196 hasVolume "128" @default.
• W2600140196 isParatext "false" @default.
• W2600140196 isRetracted "false" @default.
• W2600140196 magId "2600140196" @default.
• W2600140196 workType "article" @default.